At the news
? NEUTRALIMPACT 1/10 COURT-RULING filed Jul 20, 2026 at 20:00 ET
The District Court of New Jersey granted a joint motion to seal claim construction briefs and related exhibits in the patent infringement case between Novo Nordisk and Apotex concerning Rybelsus (GLP-1 drug). This is a routine procedural sealing order to protect trade secrets; no substantive ruling on patent validity or infringement was made. The case continues on the merits.
- Court granted joint motion to seal Markman briefs and supporting declarations as trade secrets
- No ruling on patent validity, infringement, or damages
- Case continues; next step is claim construction, which remains sealed
- Ruling is purely procedural, no financial or operational impact on Novo Nordisk
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access